TopologView all posts »
Dabigatran: Crossing a remarkable thresholdOct 14, 2009 11:00 EDT
The exciting results of the RE-LY trial appear to mark the beginning of a new era in anticoagulation for atrial fibrillation. Will dabigatran be the drug to replace warfarin, at last? How do you think these findings will improve patient care?
Disclosure: I have no relationship with the dabigatran's manufacturer (Boehringer Ingleheim) or any other forthcoming oral anticoagulant program in clinical development (DTI, Factor Xa, etc).